93M1 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt relative to equity gives MPH substantial financial flexibility and reduces fixed financing pressure. This conservative structure can help the holding company withstand weaker portfolio performance while preserving capacity to manage or develop healthcare investments.
Returned ProfitabilityA return to consistently positive earnings since 2022, including an approximately 8% net margin in 2025, indicates improved profitability after earlier losses. If maintained, this provides a stronger base for distributions, reinvestment, and portfolio management.
Healthcare Portfolio ExposureExposure to both pharmaceuticals and healthcare services gives MPH a focused investment platform within a structurally important sector. Managing several healthcare-related holdings can provide broader participation in sector growth than relying on one operating product line.
Bears Say
Erratic RevenueHighly erratic revenue and a 62.4% reported decline make the top-line contribution difficult to forecast. This reduces confidence in the durability of growth, complicates portfolio planning, and may cause profitability to vary materially between reporting periods.
Volatile Cash GenerationRepeated negative operating and free cash flow, including a sharp deterioration in 2025, weakens confidence that reported earnings consistently convert into cash. Volatile cash generation limits self-funding capacity and can constrain dependable distributions or investment activity.
Investment-Driven Earnings RiskBecause MPH primarily earns through portfolio distributions, investment-value changes, and realized gains, results depend heavily on underlying holdings rather than recurring operating sales. This can make earnings less predictable and expose the company to sustained swings in portfolio performance.
93M1 FAQ
What was MPH Health Care AG’s price range in the past 12 months?
Currently, no data Available
What is MPH Health Care AG’s market cap?
MPH Health Care AG’s market cap is CHF109.86M.
When is MPH Health Care AG’s upcoming earnings report date?
MPH Health Care AG’s upcoming earnings report date is Nov 25, 2026 which is in 28 days.
How were MPH Health Care AG’s earnings last quarter?
MPH Health Care AG released its earnings results on Sep 16, 2026. The company reported $1.106 earnings per share for the quarter.
Is MPH Health Care AG overvalued?
According to Wall Street analysts MPH Health Care AG’s price is currently Undervalued.
Does MPH Health Care AG pay dividends?
MPH Health Care AG does not currently pay dividends.
What is MPH Health Care AG’s EPS estimate?
MPH Health Care AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does MPH Health Care AG have?
Currently, no data Available
What happened to MPH Health Care AG’s price movement after its last earnings report?
MPH Health Care AG reported an EPS of $1.106 in its last earnings report. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of MPH Health Care AG?
Currently, no hedge funds are holding shares in CH:93M1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
MPH Health Care AG Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
87.92%
12-Months-Change
Fundamentals
Return on Equity
43.53%
Trailing 12-Months
Asset Growth
21.86%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
MPH Health Care AG
MPH Health Care AG is a German-based investment firm with a primary focus on the healthcare sector. The company's portfolio includes the production and distribution of medicinal products designed to treat serious illnesses like cancer, HIV, and various other chronic conditions. Beyond pharmaceuticals, it also delivers medical aesthetic treatments, develops and markets a diverse array of pharmaceutical and medical items, and furnishes related services and specialized medical devices for use in aesthetic surgery and cosmetic dermatology. Furthermore, its operations extend to supplying cytostatic solutions and involvement in real estate ventures. Established in Berlin in 2008, the company adopted its current name, MPH Health Care AG, in 2017, having previously been known as MPH Mittelständische Pharma Holding AG. It functions as a subsidiary of Magnum AG.